UNSPSC 51262406: Reproterol

This classification denotes a metaproterenol analog, adrenergic beta-agonists, and bronchodilator agent with the molecular formula C18H23N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11941YC6RN, chemically known as 1,2,3,6-tetrahydro-1,3-dimethyl-7-(3-((beta,3,5-trihydroxyphenethyl)amino)propyl)-2,6-purindion but generally known as reproterol, which bears US NIH Compound Identifier 25654. European Medicines Agency schedules Reproterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10283MIG.

UNSPSC 51262406 Reproterol, a Commodity code, nominally describes a specific pharmaceutical product, but recent state and local opportunities tagged under this code reveal a mismatch between the code's narrow scope and the actual procurement activity. Seminole County, Florida posted an IFB in June 2026 seeking naloxone and drug deactivation systems — opioid-response supplies wholly unrelated to reproterol's pharmaceutical profile. The Texas Health and Human Services Commission issued an RFI in April 2026 focused on direct-to-manufacturer prescription fulfillment and pharmacy benefit program restructuring, also tangential to the code's nominal classification. The code shows little relevant recent activity aligned with its stated product line; the opportunities present indicate either tagging errors or a pattern of state and local procurement offices using the code as a catch-all for pharmaceutical-adjacent purchases that do not fit standard commodity categories.

Activity under this code is sparse and geographically limited to recent notices from Florida and Texas. Seminole County's naloxone and deactivation-systems IFB (solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county health building, via competitive bidding with electronic submission through the county e-procurement portal. The Texas HHS RFI (HHS0017013, due April 3, 2026) pursued market intelligence on pharmacy benefit restructuring and direct manufacturer contracting rather than a specific product procurement. Given the weak alignment between the code's definition and the solicitations tagged to it, firms evaluating this code should treat recent activity as a signal of procurement-classification ambiguity rather than a clear demand signal for reproterol or related products.